Oxurion NV OXUR-BE:Euronext Brussels

*Data is delayed | EUR
Last | 02/26/21 CET
2.56quote price arrow down-0.06 (-2.29%)
Volume
35,829
52 week range
2.14 - 3.31

...

Loading . . .

KEY STATS

  • Open2.61
  • Day High2.65
  • Day Low2.56
  • Prev Close2.62
  • 52 Week High3.31
  • 52 Week High Date06/24/20
  • 52 Week Low2.14
  • 52 Week Low Date03/17/20
  • Market Cap118.82M
  • Shares Out38.29M
  • 10 Day Average Volume28,988.33
  • Dividend-
  • Dividend Yield-
  • Beta1.04
  • 1 Year % Change-13.37

RATIOS/PROFITABILITY

  • EPS (TTM)-0.81
  • P/E (TTM)-3.17
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Oxurion NV News

There is no recent news for this security.

Latest OXUR-BE News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Oxurion NV, formerly known as ThromboGenics NV, is a Belgium-based biopharmaceutical company, which focuses on the development and commercialization of ophthalmic medicines. Its lead product, JETREA (ocriplasmin), has been approved by the United States Food and Drug Administration for the treatment of symptomatic vitreomacular adhesion (VMA) and was launched in January 2013. Oxurion partners with Alcon (Novartis) for the commercialization of JETREA outside the United States....
Thomas Clay
Non-Executive Chairman
Patrik De Haes M.D.
Chief Executive Officer
Tom Graney
Chief Financial Officer
Address
Gaston Geenslaan 1
Heverlee
3001
Belgium